Allakos drops a pair of duds on patient-reported symptom relief for GI disease, vaporizing billions off its value
Targeting overactive white blood cells known as eosinophils has become a hot drug target with multiple approvals in recent years. One company with big platform hopes targeting those cells has now blown up in spectacular fashion after a lead drug showed little symptom relief for patients.
In two separate Phase II/III studies across multiple types of eosinophilic gastrointestinal disease, Allakos’ lirentelimab showed a significant reduction in eosinophil levels in the blood, but those results didn’t carry over into alleviating symptoms. On co-primary endpoints in both studies of self-reported symptom relief, patients didn’t see any significant improvement over placebo.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters